The B-ly4 monoclonal antibody specifically binds to CD21, a 145 kDa glycosylated type I integral membrane protein. CD21 is a receptor for the C3d complement fragment and for Epstein-Barr virus (EBV). CD21 is expressed on mature B cells, follicular dendritic cells, and some epithelial cells. It is also weakly expressed on the subset of mature T cells and thymocytes. CD21 plays a role in B-cell activation and proliferation. It may also play a role in modulating the function of T cells in the immune response to infections by lymphotropic viruses. Recently, CD21 was found to be part of a large complex containing CD19, CD81, and possibly other molecules.
The antibody was conjugated to an oligonucleotide that contains an antibody clone-specific barcode (ABC) flanked by a poly-A tail on the 3' end and a PCR handle (PCR primer binding site) on the 5' end. The ABC for this antibody was designed to be used with other BD AbSeq oligonucleotides conjugated to other antibodies. All AbSeq ABC sequences were selected in silico to be unique from human and mouse genomes, have low predicted secondary structure, and have high Hamming distance within the BD AbSeq portfolio, to allow for sequencing error correction and unique mapping. The poly-A tail of the oligonucleotide allows the ABC to be captured by the BD Rhapsody™ system or other oligo-dT-based capture systems. The 5' PCR handle allows for efficient sequencing library generation for Illumina sequencing platforms.